Actively Recruiting
Phase 2 Study of Weekly Paclitaxel or Nab-Paclitaxel Combined With Pembrolizumab and Mirabegron for Treating Recurrent Ovarian Cancer in Adult Women
Led by Obstetrics & Gynecology Hospital of Fudan University · Updated on 2025-12-19
20
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a drug regimen combining weekly paclitaxel or nab-paclitaxel, pembrolizumab, and mirabegron to treat adults with relapsed ovarian cancer. This Phase II study aims to determine if this combination reduces tumor size and to understand what medical issues participants might experience while taking these drugs. Participants will receive weekly doses of paclitaxel or nab-paclitaxel and pembrolizumab every 21 days through intravenous infusion. They will also take mirabegron orally every day starting on Day 1 of each 21-day cycle. Treatment continues until participants cannot tolerate it or their disease progresses. During the study, participants will visit the clinic every two months for checkups and tests. They will keep a diary to record symptoms. Researchers will measure tumor response at 6 months and monitor survival and progression at 6 and 12 months. Safety is assessed by tracking severe side effects up to one month after treatment ends. The study runs from December 2025 to November 2028.
CONDITIONS
Brief Title
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Research Team
C
Cao, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here